Cancer-associated extracellular vesicles (EVs) are intimately involved in establishment of tumor microenvironment and occurrence of metastasis. However, previous studies have mainly relied on experiments with cultured cell lines or mouse models, making it difficult to gain a full understanding of EV functions in human body. Hence, we extracted EVs directly from surgically resected viable clear cell renal cell carcinoma (ccRCC) tissues and adjacent normal renal tissues (n 5 20). Quantitative LC/MS analysis identified 3,871 tissue-exudative EV (Te-EV) proteins, among which azurocidin (AZU1) was highly enriched in tumor Te-EVs (p 5 2.85 3 10
Renal cell carcinoma (RCC) represents the leading cause of cancer death among urological malignancies, 1 and clear cell renal cell carcinoma (ccRCC) is its most common histological subtype. The prognosis for early-stage ccRCC is usually good, with a 5-year survival rate of about 90%, however this rate drops to about 10% in ccRCC patients with metastasis. Large number of early-stage ccRCC cases are asymptomatic, with approximately one-third of all patients presenting with locally metastatic cancer at the time of diagnosis. 2, 3 Therefore, a better understanding of the molecular mechanisms of ccRCC progression is crucial for the discovery of novel prognostic markers and targeted therapies. EVs, including exosomes, microvesicles, and apoptotic bodies, are released by almost all cell types, including tumor cells. Through transfer of their cargo (miRNAs, mRNAs, and proteins), EVs are capable of affecting the signaling pathway of recipient cells. 4, 5 Increasing evidence suggests a pivotal role for EVs in mediating intercellular communications for multiple aspects of tumor development, including angiogenesis, immune suppression, and metastasis. [6] [7] [8] [9] Moreover, EVs have been reported to potentially prime metastatic sites for tumor cells through the unique composition of specific integrins that they deliver as cargo. 10 However, previous EVrelated studies have mainly focused on exosomes derived from cultured cells, and there is little data comparing EVs collected from tumor cells to those from normal cells from the same histological background. Therefore, to understand cancer-associated EV functions in the human body, we attempted to obtain EVs from freshly resected ccRCC tissue (tumor and adjacent normal renal tissue) by means of a brief incubation in serum-free medium, yielding what we term tissue-exudative extracellular vesicles (Te-EVs).
To our knowledge, this is the first study showing proteome-wide comparative characteristics for EVs directly derived from ccRCC and normal renal tissues. We here report identification of azurocidin (AZU1) as an EV-protein highly expressed in tumor-derived EVs. In our subsequent functional analyses for EV-AZU1, engagement with vesiclemediated hematogenous metastasis of RCC is discussed.
Material and Methods

Chemicals and antibodies
Monoclonal anti-CD9 antibody (12A12), monoclonal anti-CD63 antibody (8A12), and monoclonal anti-CD81 antibody (12C4) which were previously confirmed the specificity 11, 12 were purchased from Cosmo Bio. Monoclonal anti-AZU1 antibody (ab181989), polyclonal anti-mouse IgG 20 nm gold preadsorbed antibody (ab27242), and polyclonal antirabbit IgG 40 nm gold preadsorbed antibody (ab119180) were purchased from Abcam. Monoclonal anti-b-tubulin antibody (T8328) and monoclonal anti-FLAG M2 antibody (F1804) were purchased from Sigma Aldrich. The C terminal FLAGtagged AZU1 inserted into pcDNA3.1 (pcDNA3.1/AZU1-FLAG) was purchased from Addgene (OHu03670D). The pcDNA3.1 (1) empty vector were kindly gifted by Dr. Wataru Nakata (Osaka University). pcDNA6.2-GW/EmGFPmiR vector and pcDNA6.2-GW/EmGFP-miR-neg control plasmid were purchased from Thermo Fisher Scientific.
Clinical specimens
The ccRCC specimens were obtained from patients undergoing primary resection at the Osaka University Medical Hospital, Japan. Tumor-associated normal renal tissue was also obtained from a subset of these patients when possible. Histological diagnosis was established with standard hematoxylin and eosin-stained sections by two senior pathologists experienced in RCC diagnosis. Tumors were staged according to the 6th AJCC TNM staging system and graded according to Fuhrman's nuclear grading system. Written informed consent was obtained from each patient, and the study was approved by the ethics review board of both the Osaka University Medical Hospital and Japanese Foundation for Cancer Research. The pathological information of clinical tissue and serum samples are shown in Supporting Information Tables  1 and 2 .
Cell culture
Four human ccRCC cell lines (786-O, Caki-1, Caki-2, and ACHN), obtained from the American Type Culture Collection (ATCC), were cultured in RPMI1640 medium (Wako) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin G, and 0.1 lg/ml streptomycin. HUVEC cells (Gibco) were cultured in Medium 200 supplemented with large vessel endothelial supplement (Gibco).
Purification of extracellular vesicles
Following excision, the tissue samples were immediately immersed in 4 ml DMEM medium (Wako) without FCS and stored at 48C for 1 h. Tissue-immersed medium was then centrifuged at 2,0003g, for 30 min, and the collected supernatants were subjected to the ultracentrifuge method for recovery of Te-EVs (Supporting Information Fig. S1 ). The protein concentration of obtained tissue-exudative EVs was measured using Micro BCA protein assay kit (Thermo Fisher Scientific). The approximate number of cells per tissue sample (wet weight) from which the Te-EVs were collected was as follows: 15.91 6 4 3 10 4 cells/mg for normal renal tissue and 96.31 6 10 3 10 4 cells/mg for ccRCC tissue. For purification of CM-EVs, ccRCC cell lines (786-O, ACHN, Caki-1, and Caki-2) were seeded into three 10 cm dishes (5.0 3 10 5 cells/dish) and incubated for 48 h. Cellcultured medium (RPMI1640) was then centrifuged at 2,0003g, for 30 min, 16,0003g, for 30 min and the collected supernatants were subjected to the ultracentrifuge method for recovery of extracellular vesicles. The protein concentration of obtained CM-EVs was measured using Micro BCA protein assay kit (Thermo Fisher Scientific). Serum EVs from xenograted-mice were isolated using total exosome isolation (from serum) (Thermo Fisher Scientific). Healthy control serum EVs and ccRCC serum EVs were isolated using EVSecond columns (GL Sciences) following the manufacturer's instruction.
Western blotting
Cells were lysed with Laemmli SDS-sample buffer containing 5% 2-mercaptoethanol. EV samples were lysed with Laemmli SDS-sample buffer with or without 2-mercaptoethanol. Protein samples were separated on a 7.5-15% sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) gel and then transferred to a polyvinylidene difluoride membrane using the Bio-Rad semidry transfer system (1 h, 12 V). Immunoreactive proteins made to react with the antibodies described previously were visualized by treatment with a . For serum EV protein cargo analysis, samples were standardized by using the same starting volume of serum for each sample.
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Establishment of cell lines with stable AZU1-FLAG expression
The vector expressing AZU1-FLAG (pcDNA3.1/AZU1-FLAG) or empty vector (pcDNA3.1) was transfected into ACHN cells and cultured in a medium containing 2 lg/ml G418 (Roche) for selection.
Establishment of AZU1-FLAG stable cell-xenografted mice
Female NOD-SCID mice were obtained from Oriental Yeast Corporation. Seven week-old-mice were used for AZU1-FLAG stable cell-xenografted mice experiments. Animals were kept under 12 h light-dark cycles at 22-248C. ACHN-AZU1-FLAG (ACHN-AZU1) and ACHN-empty vector (ACHN-Ctrl) cells were both adjusted to a concentration of 1.0 3 10 7 cells suspended in 50 ll serum-free RPMI1640. The cell suspensions with 50 ll matrigel (Corning) were then injected subcutaneously into right flanks of NOD-SCID mice (ACHN-AZU1, N 5 5; ACHN-Ctrl, N 5 5). All procedures were performed under a protocol approved by the Animal Experimentation Committee at Osaka University.
Developed tumors were resected 32 days after xenografts. Blood from mice was collected from external jugular vein under general anesthesia. Sera was separated by centrifugation (2,0003g, for 30 min) at 48C. 
EV incorporation assay
Establishment of cell lines with stable miAZU1 expression
Pri-miRNA insert against AZU1 (Hmi401460_AZU1) was purchased from Thermo Fisher Scientific and cloned into pcDNA6.2-GW/EmGFP-miR vector. pcDNA6.2-GW/EmGFPmiR-neg control plasmid was also purchased from Thermo Fisher Scientific. The vector expressing miRNA against AZU1 (miAZU1) or control (miCtrl) was transfected into ACHN cells with stable AZU1-FLAG expression and cultured in a medium containing 10 lg/mL blasticidin for selection.
Tube formation assay
The ccRCC CM-EVs (10 lg/mL) or Te-EVs (50 lg/mL) were incubated with HUVEC cells and subjected to a tube formation assay following the manufacturer's (Thermo Fisher Scientific) instruction. Briefly, ccRCC CM-EVs (10 lg/ml) or Te-EVs (50 g/ml) were treated when HUVEC cells (8.0 3 10 4 /well) were reseeded on Geltrex Matrix-coated 24 well plate (Gibco). At 16 h postseeding, the cells were stained with 2 lg/ml of calcein AM (Gibco) and incubated for 30 min at 378C, 5% CO 2 . Total tube length was calculated using the NIH Image J software.
Transendothelial migration assay
HUVEC cells (4.0 3 10 4 /well) in endothelial cell basal medium were plated per well (8 lm pore size 24 well cell culture insert: Fisher Scientific) on to fibronectin surfaces and allowed to form confluent monolayers for 4 days at 378C, 5% CO 2 and the cells were treated with EVs (10 lg/ml) for 24 h. 
Statistics
In mass spectrometric comparative analysis for pairs of normal and tumor Te-EVs, paired t test was used, in which F test was preliminarily performed for verifying equality of variance. Proteins that were significantly up-or downregulated in tumor Te-EVs were defined using the thresholds, p < 0.05, fold-change >2.0, and valid value >80%. For all the other experiments, results were expressed as the mean 6 standard deviation of the mean (SD) or median. Differences between the values were statistically analyzed using the Student's t test or one-way analysis of variance (ANOVA) with Bonferroni post hoc tests (GraphPad Prism 6.0, GraphPad software). A p values of <0.05 was considered statistically significant. The tumor stage-or grade-dependent trend of EV-AZU1 level was assessed using Jonckheere-Terpstra test (R version 2.13.0 with the RcmdrPlugin.EZR package, Saitama Medical Center, Jichi Medical University, Japan). Association of lymphatic invasion status or gender with EV-AZU1 level was tested by Mann-Whitney U test. Correlation of patients' age with EV-AZU1 level was calculated based on Pearson's correlation coefficient analysis.
RESULTS
Isolation of extracellular vesicles from cultured patientderived tissue
The scheme for comparative proteome profiling of Te-EVs is shown in Figure 1a . Resected paired tissue samples (n 5 20) were cultured in serum-free DMEM medium and Te-EVs were purified by the sequential ultracentrifugation method (Supporting Information Fig. S1 ). The quality of isolated EVs was evaluated by western blotting analysis (Fig. 1b) and mass spectrometric identification (Supporting Information Fig. S2) for tetraspanins as classical exosome marker proteins. Detection of 15 tetraspanins clearly illustrated the purity of TeEVs (Supporting Information Fig. S2 ). Interestingly, most of tetraspanins were significantly downregulated in tumorderived EVs compared to normal-derived EVs.
Transmission electron microscope (TEM) analysis (Fig.  1c) illustrated that most of the isolated particles expressed a general EV marker protein CD9 on their surfaces. Additionally, these images and the nanoparticle tracking analysis (NTA, Figs. 1d and 1e ) results revealed that the mean diameter of Te-EVs isolated from ccRCC tissues (tumor Te-EVs) and those from normal renal tissues (normal Te-EVs) were between 50 and 200 nm (Figs. 1ce) (Figs. 1d and 1e) , although the biogenesis mechanisms and functional relevance remain to be elucidated. These results confirmed that EVs were successfully isolated from fresh viable patient-derived tissues by short-term culture followed by the standard ultracentrifugation method.
Comprehensive protein cargo analysis of Te-EVs
Isolated Te-EV samples (20 matched pairs) were subjected to high resolution LC/MS analysis. Protein identification and quantification analysis by MaxQuant software identified a total 3,871 proteins from the Te-EVs (FDR < 1%), of which 160 or 253 proteins were specifically identified from normal or tumor Te-EVs, respectively (Fig. 2a) . Gene ontology enrichment analysis revealed that specific integral membrane proteins (Fig. 2b) , proteins in metabolic processes (Fig. 2c) , and nucleotide binding proteins (Fig. 2d) were preferentially enriched in tumor Te-EVs. Additionally, in comparison with cells, secreted EVs possessed a distinct protein composition, with a significantly higher level of membrane proteins and vastly fewer nuclear proteins (Fig. 2b) . These proteome-wide characteristics indicate that biogenesis of EVs might be regulated by selective protein sorting machinery which, especially in cancer cells, loads proteins controlling various cancerassociated events.
To elucidate biological functions of ccRCC-derived EVs, proteins expressed specifically in tumor Te-EVs were extracted from 3,871 identified proteins and analyzed by paired t test. As a result, 106 or 291 proteins were identified as significantly upregulated or downregulated factors in tumor Te-EVs compared to normal ones, respectively (Fig.  3a , Supporting Information Table 3 ). The 3D PCA plot clearly illustrated that the 106 proteins upregulated in tumor Te-EVs can statistically discern tumor group from normal group (Fig. 3b) . Among the 106 upregulated proteins, we focused on azurocidin (AZU1) as having the greatest distance from the origin in the volcano plot (p 5 2.85 3 10
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, foldchange 5 31.59, indicated by an red arrow in Fig. 3a) . The identified MS/MS spectra corresponding to 6 AZU1-derived peptides are shown in Supporting Information Figure S3 and Supporting Information Table 4 . In all 20 ccRCC patients, AZU1 was drastically upregulated in tumor Te-EVs (Fig. 3c) . More importantly, AZU1 content increased with more advanced ccRCC pathological stages and grades (Fig. 3d , Supporting Information Table 5 , Jonckheere-Terpstra test; pathological stage: p 5 0.018, grade: p 5 0.010). The mass spectrometric quantification results were further confirmed by western blotting analysis (Fig. 3e) . Since tumor-infiltrated polymorphonuclear leukocytes (PMNs) stores AZU1 in its secretory vesicles and primary granules, we verified whether AZU1 identified in tumor Te-EVs was ccRCC cell origin. Molecular weight of AZU1 in tumor Te-EVs was identical to whole cell lysate of 786-O ccRCC cells (35 kDa), while AZU1 in PMNs was 29 kDa (Supporting Information Figure S4 ), indicating that AZU1 identified in tumor Te-EVs should be derived from ccRCC cells rather than PMNs. Indeed, different glycoforms were reported for AZU1 expressed in PMNs (29 kDa) or non-PMN tumor cells (34.5-37 kDa).
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The ccRCC-derived EVs regulate permeability of the vascular endothelial cell layer in an AZU1-dependent manner Since ccRCC tissue is known to have abundant blood vessels that play important roles in the construction of the ccRCC microenvironment, [18] [19] [20] [21] we examined the biological effects of AZU1-overexpressed EVs (AZU1 11 EVs) on vascular endothelial morphology. First endogenous localization and expression levels of AZU1 were evaluated in Figures 4a and 4b . The transmission electron microscopy (TEM) images illustrated co-localization of AZU1 and CD9 on the surface of EVs. The EVs isolated from cultured media (CM-EVs) of 4 RCC cell lines expressed AZU1 except for ACHN cells. Next we observed efficient incorporation of ccRCC CM-EVs or Te-EVs into HUVEC cells (Supporting Information Figs. S5A or 5B, respectively). When we performed a HUVEC tube formation assay using ccRCC CM-EVs or Te-EVs, the length of formed tubes was not significantly affected by treatment with EVs (Supporting Information Figs. S6A or S6B, respectively), indicating that ccRCC EVs do not stimulate angiogenesis in vitro.
Next, we examined the effect of ccRCC CM-EVs on the permeability of the vascular endothelial cell layer by measuring the transendothelial electrical resistance (TEER). After 24 h incubation with CM-EVs, the TEER of HUVEC cell sheets was remarkably decreased especially in the presence of EVs from Caki-1 or 786-O cells (Fig. 4c) . Given the expression levels of AZU1 in Figure 4bs expressing more AZU1 on the surface displayed a stronger permeabilization effect.
We further confirmed AZU1's capacity for cell sheet permeabilization using an exogenous overexpression system for AZU1. As shown in Figure 4dHN cells expressing AZU1-FLAG secreted EVs containing high levels of AZU1-FLAG, while endogenous AZU1 was hardly detectable in nontreated ACHN cells (Fig. 4b) . The TEM analysis indicated that the intravesicular localization of AZU1-FLAG was identical to that of endogenous AZU1 (Figs. 4a and 4e) . Next, in the HUVEC permeabilization assay, CM-EVs overexpressing AZU1 showed significantly enhanced TEER reduction compared to those derived from mock vector-transfected ACHN cells (Fig. 4f) . Conversely, CM-EVs from miAZU1-expressing cells attenuated the effect of CM-EVs-induced TEER reduction (Supporting Information Figs. S7A and S7B) . Moreover, HUVEC cell sheet treated with CM-EVs overexpressing AZU1 showed increased cell number of transmigrated cells compared to those derived from mock vector-transfected ACHN cells (Fig. 4g) . These results provide strong evidence that AZU1 from ccRCC EVs is a key regulator for disruption of vascular endothelial morphology.
EV-AZU1 is present in sera of ccRCC patients
Since tumor-derived EVs are thought to be also detectable in blood circulation, [8] [9] [10] [22] [23] [24] first we examined the presence of EV-AZU1 in sera of AZU1-FLAG cell-xenografted mice by Western blotting. EV-AZU1 was detected not only in sera of xenografted mice but also in tumor Te-EVs (Fig. 5a ). Next, we examined the AZU1 content of serum-derived EVs using sera of healthy controls (n 5 10) and ccRCC patients (n 5 19) by quantitative mass spectrometry. Interestingly, AZU1 was specifically detected in 10 ccRCC patients, but not in healthy controls (sensitivity 5 52.6% and specificity 5 100%) (Fig. 5b , Supporting Information Fig. S8 , and Supporting Information Table 5 ), suggesting that tumor-derived EV-AZU1 is detectable in blood circulation. Finally, cell sheet permeabilization activity was evaluated using tumor or normal EVs derived from ccRCC patients (Figs. 6a and 6b) . Tumor Te-EVs but not normal Te-EVs upregulated HUVEC cell permeability, even after 12 h of coincubation. Te-EVs from No. 17 and 36 showed strong expression of AZU1 (Supporting Information Fig. S9 ), which also demonstrated more significant reduction of TEER in Figure 6a . In addition, when a mixture containing equal amounts of normal and tumor Te-EVs was co-cultured with HUVEC cells, both types of Te-EVs were uniformly incorporated into recipient cells (Fig. 6c) , suggesting that the permeabilization activity of ccRCC EVs in Figure 6a are regulated by the function of specific cargoes rather than the incorporation efficiency of EVs. These mixtures of normal and tumor Te-EVs, which may well reflect the actual situation in the human body, also demonstrated considerable capacity to collapse the vascular endothelial cell layer (Fig. 6d) . Data in Figures 4-6 explicitly suggest the possibility that AZU1 11 -EVs produced by ccRCC cells would facilitate hematogenous metastasis of ccRCC cells themselves.
DISCUSSION
The present study marks the first successful isolation and molecular characterization of EVs secreted from viable human tissue specimens (Te-EVs). Studying Te-EVs can provide four notable advantages over cell culture-derived EVs in both the discovery of EV biomarkers and interpretation of EV functions.
(1) The Te-EVs more accurately reflect most physiological characteristics and behaviors of EVs in human body. Indeed, it is tremendously important to analyze EVs derived from fresh clinical samples, rather than from cultured cell lines, because biogenesis of EVs is likely to be strongly affected by complex reciprocal communications between surrounding cells or remote organs. (2) To identify cancerspecific cargoes (biomarkers) in EVs, adequate controls are necessary for precise differential analysis. As shown in this Table 1 ). Sample numbers in each group were indicated in parentheses at the bottom. Stage: † p < 0.05 vs. 1a; **p < 0.01 vs. N. Grade: **p < 0.01 vs. N. One-way ANOVA. (e) Upregulation of AZU1 in tumor Te-EVs is confirmed by western blotting analysis using 500 ng of EV samples per lane from 12 independent resected tissues. Uncropped Western blot data is shown in Supporting Information Figure. S12 . study, Te-EV analysis allows intra-individual comparison of EV components using EVs from cancer tissues and adjacent normal tissues, which possess common biological background. (3) In contrast to body fluid samples, only minimal contaminants are involved in Te-EV samples, including serum abundant proteins or whole body-derived EVs. This fact helps us to deal with high-purity organ-specific EVs without any laborious EV purification steps, eventually allowing to in-depth OMICS-wide analysis of EVs as shown in the present proteomic study. (4) Undoubtedly proteins are not biochemically amplifiable. However, we can amplify Te-EVs as a biomarker resource by prolonged incubation of viable tissues, allowing effective biomarker discovery even from a tiny portion of biopsy sample for instance.
From the gene ontology enrichment analysis, we found that normal Te-EVs were enriched for proteins necessary for maintaining normal renal cells (e.g., mitochondrial respiration and proton-transportation) compared to Te-EVs from ccRCC cells. 25, 26 On the other hand, tumor Te-EVs were enriched with various membrane proteins. Since the specificity of targeting EVs to particular recipient cells is thought to depend on the surface ligands present on both, 27, 28 tumor cells might improve their EV's specificity and/or potency by increasing the presence of various membrane proteins on the EV surface, thus allowing cancer cells better EV-mediated control of the tumor microenvironment.
We found that a protein enriched in the tumor Te-EVs, AZU1, was also specifically elevated in serum EVs from ccRCC patients compared to those from healthy controls. Moreover, EV-AZU1 was present in sera of AZU1-FLAG cell-xenografted mice, suggesting that EV-AZU1 secreted from tumor cells is in blood circulation of ccRCC patients. AZU1 has been identified as a chemoattractant and an activator of monocytes and macrophages, as it is stored in the secretory vesicles and primary granules of neutrophils. 29, 30 Tumor associated macrophage (TAM) is known to be attracted by chemokines and cytokines produced by tumor cells, leading to construction of tumor microenvironment which supports cancer cell proliferation. Moreover, increased density of TAMs is associated with poor survival of ccRCC patients. 31 Since AZU1 was originally reported as a chemoattractant and an activator of monocytes and macrophages, tumor-derived EV-AZU1 might be involved in developmental induction (maturation) and/or spatial accumulation of TAM in ccRCC microenvironment.
In addition, AZU1 released from the neutrophils has been reported as to act on endothelial cells, causing vascular leakage. [32] [33] [34] Importantly, it is known that AZU1 binds to heparan sulfate and has serine-type endopeptidase activity. Since vascular endothelial cells express heparan sulfate proteoglycans on their surface, overexpressed AZU1 on the ccRCCderived EVs might play two roles, first by enhancing the binding affinity of ccRCC-derived EVs onto the surface of vascular endothelial cells and second by subsequently inducing proteolysis of tight junctions among these cells, resulting in disruption of vascular endothelial layer structures and promote ccRCC cell endothelial transmigration as demonstrated in Figures 4 and 6 . According to the cancer genome atlas, AZU1 expression is upregulated in breast cancer, prostate cancer, and colorectal cancer (Supporting Information Fig.  S10 ). Therefore EVs derived from such type of cancer cells might also function as permeabilizer. On the other hand, tumor cells induce conformational FAK activation through multiple mechanisms via secretion of growth factors and activation of endothelial cell-specific receptors, leading to upregulated vascular permeability and subsequent tumor cell intravasation and metastasis. 35, 36 Growing evidence supports the idea that tumor cell-derived EVs have the potential to manipulate the tumor microenvironment by regulating immune cells, endothelial cells, and the tumor cells themselves. [37] [38] [39] These facts coordinately support our results, indicating that ccRCC cells might utilize AZU1
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-EVs in addition to cytokines as accelerators of hematogenous metastasis.
Although AZU1 protein levels was significantly higher in ccRCC tissues compared to adjacent normal tissues (Supporting Information Figs. S11A and S11B), neither stage-nor gradedependent regulation was found (Supporting Information Figs. S11C and S11D). Therefore the expression level in original tissue was not a critical determinant for stage-or grade-dependent upregulation of AZU1 content in EVs (Fig. 3d) .
Currently, RCC is in most cases incidentally diagnosed by ultrasound or abdominal computed tomography, performed for non-specific clinical signs. Given the fact that 5-year survival rate of stage-IV RCC is <20%, the early detection should be one of the most fundamental ways to improve the prognosis of RCC. However, with regard to the molecular basis of RCC, no biomarker molecules are currently available for specific detection of RCC especially at the early stage. In the present study, we propose that Te-EVs cargo (e.g., protein, mRNA, miRNA, and DNA) might be an ideal resource for searching biomarkers for liquid biopsy as well as investigating physiological EV functions. The Jonckheere-Terpstra test showed that stagedependent escalation of AZU1 level was observed in Te-EV samples (Fig. 3d) , but not in serum samples (Supporting Information Table 5 ). This discrepancy may reflect AZU1-dependent interaction between EVs and vascular endothelial cells.
It is known that AZU1 specifically binds to heparan sulfate proteoglycans which abundantly express on the surface of vascular endothelial cells. Therefore EVs with higher AZU1 content (secreted from higher stage or grade tumor cells) could more strongly bind to inner surface of blood vessels, resulting in adsorptive depletion of AZU11-EVs from circulation.
Indeed Te-EVs from advanced stage ccRCC tissues had a tendency to demonstrate stronger interaction with the HUVEC cell layer (Fig. 6a) . Thus, we think there is no significant correlation between concentration of serum EV-AZU1 and stages of RCC progression, nonetheless EV-AZU1 would have a great potential as an early detection biomarker for RCC which could be measured by non-invasive serological test.
In summary, this is the first experimental record reporting extraction of EVs from viable human tissue samples (Te-EVs) and identification of a novel permeabilizer for vascular endothelial cells, EV-AZU1. We believe that integrated OMICS analyses of RNAs, proteins, and metabolites in Te-EVs will open an exciting new avenue to understanding physiological functions of EVs in various diseases. 
